Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

Por Momtaz, Parisa, Postow, Michael A
Publicado no Pharmgenomics Pers Med (2014)

Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

Por Postow, Michael A, Robson, Mark E
Publicado em 2012

Combinations of Radiotherapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

Por Barker, Christopher A., Postow, Michael A.
Publicado no Int J Radiat Oncol Biol Phys (2014)

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Por Friedman, Claire F., Postow, Michael A.
Publicado no Curr Oncol Rep (2016)

Targeting Immune Checkpoints: Releasing the Restraints on Anti-tumor Immunity for Patients with Melanoma

Por Postow, Michael A., Harding, James, Wolchok, Jedd D.
Publicado em 2012

Immunomodulatory Therapy for Melanoma: Ipilimumab and Beyond

Por Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Publicado em 2013

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Por Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Publicado no Front Oncol (2015)

Immune Checkpoint Blockade in Cancer Therapy

Por Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Publicado no J Clin Oncol (2015)

Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy In Need of Further Investigation

Por Escorcia, Freddy E., Postow, Michael A., Barker, Christopher A.
Publicado no Cancer J (2017)

Ipilimumab in patients with melanoma and autoimmune disease

Por Kyi, Chrisann, Carvajal, Richard D, Wolchok, Jedd D, Postow, Michael A
Publicado em 2014

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

Por Page, David B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Publicado em 2013

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

Por Ryder, Mabel, Callahan, Margaret, Postow, Michael A, Wolchok, Jedd, Fagin, James A
Publicado no Endocr Relat Cancer (2014)

Opportunistic infections in patients treated with immunotherapy for cancer

Por Kyi, Chrisann, Hellmann, Matthew D, Wolchok, Jedd D, Chapman, Paul B, Postow, Michael A
Publicado em 2014

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

Por Gulati, Nicholas, Carvajal, Richard D., Postow, Michael A., Wolchok, Jedd D., Krueger, James G.
Publicado no Exp Dermatol (2016)

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Por Del Castillo, Maria, Romero, Fabian A., Argüello, Esther, Kyi, Chrisann, Postow, Michael A., Redelman-Sidi, Gil
Publicado no Clin Infect Dis (2016)

Safety of Infusing Ipilimumab Over 30 Minutes

Por Momtaz, Parisa, Park, Vivian, Panageas, Katherine S., Postow, Michael A., Callahan, Margaret, Wolchok, Jedd D., Chapman, Paul B.
Publicado no J Clin Oncol (2015)

Concurrent radiation therapy and ipilimumab immunotherapy for patients with melanoma

Por Barker, Christopher A., Postow, Michael A., Khan, Shaheer A., Beal, Kathryn, Parhar, Preeti K., Yamada, Yoshiya, Lee, Nancy Y., Wolchok, Jedd D.
Publicado no Cancer Immunol Res (2013)

Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment

Por Kiess, Ana P., Wolchok, Jedd D., Barker, Christopher A., Postow, Michael A., Tabar, Viviane, Huse, Jason T., Chan, Timothy A., Yamada, Yoshiya, Beal, Kathryn
Publicado no Int J Radiat Oncol Biol Phys (2015)

Liver Resection and Ablation for Metastatic Melanoma: A Single Center Experience

Por Doussot, Alexandre, Nardin, Charlée, Takaki, Haruyuki, Litchman, Tess D., D'angelica, Michael I., Jarnagin, William R., Postow, Michael A., Erinjeri, Joseph P., Kingham, T. Peter
Publicado no J Surg Oncol (2015)

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma

Por Postow, Michael A., Manuel, Manuarii, Wong, Phillip, Yuan, Jianda, Dong, Zhiwan, Liu, Cailian, Perez, Solène, Tanneau, Isabelle, Noel, Marlène, Courtier, Anaïs, Pasqual, Nicolas, Wolchok, Jedd D.
Publicado no J Immunother Cancer (2015)